ASKA Pharmaceutical Co., Ltd. Announces Consolidated Earnings Results for the First Quarter Ended June 30, 2017; Provides Earnings Guidance for the Second Quarter Ending September 2017 and for the Full Year Ending March 2018
For the second quarter ending September 2017, the company excepts nets sales of $227.3 million, operating income of $12.7 million and profit attributable to owners of parent of $11.8 million.
For the full year ending March 2018, the company excepts nets sales of $454.5 million, operating income of $18.2 million and profit attributable to owners of parent of $16.4 million.